News FDA gives green light to Chiesi's Lamzede Chiesi scores milestone US FDA approval for first AM enzyme replacement therapy, Lamzede.
News Chiesi expands rare disease portfolio with Amryt Pharma acqu... Biopharma and healthcare group Chiesi Farmaceutici S.p.A.
Views & Analysis Touring Chiesi's vision for the future at the new Biotech Ce... Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th
R&D Investing in biologics excellence In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs.